Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

Related Articles by Review for PubMed (Select 9592190)

1.

3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.

Cheung NK, Kushner BH, Yeh SD, Larson SM.

Int J Oncol. 1998 Jun;12(6):1299-306.

PMID:
9592190
2.

Monoclonal antibodies and neuroblastoma.

Miraldi F.

Semin Nucl Med. 1989 Oct;19(4):282-94. Review.

PMID:
2678480
3.

Disialoganglioside directed immunotherapy of neuroblastoma.

Modak S, Cheung NK.

Cancer Invest. 2007 Feb;25(1):67-77. Review.

PMID:
17364560
4.

Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.

Parsons K, Bernhardt B, Strickland B.

Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Review.

PMID:
23386066
5.

Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.

Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG.

Cancer Lett. 2003 Jul 18;197(1-2):205-9. Review.

PMID:
12880983
6.

Immunotherapy with GD2 specific monoclonal antibodies.

Cheung NK, Medof ME, Munn D.

Prog Clin Biol Res. 1988;271:619-32. Review. No abstract available.

PMID:
3043454
7.

Monoclonal antibody-based therapy for neuroblastoma.

Cheung NK.

Curr Oncol Rep. 2000 Nov;2(6):547-53. Review.

PMID:
11122891
8.

Treatment of high-risk neuroblastoma with anti-GD2 antibodies.

Castel V, Segura V, CaƱete A.

Clin Transl Oncol. 2010 Dec;12(12):788-93. doi: 10.1007/s12094-010-0600-y. Review.

PMID:
21156409
9.

Immunotherapy. Neuroblastoma as a model.

Cheung NK.

Pediatr Clin North Am. 1991 Apr;38(2):425-41. Review.

PMID:
2006085
10.

Immune therapies for neuroblastoma.

Navid F, Armstrong M, Barfield RC.

Cancer Biol Ther. 2009 May;8(10):874-82. Epub 2009 May 9. Review.

11.

Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies.

Cheung NK, Munn D, Kushner BH, Usmani N, Yeh SD.

Int J Rad Appl Instrum B. 1989;16(2):111-20. Review. No abstract available.

PMID:
2497088
12.

Promising therapeutic targets in neuroblastoma.

Matthay KK, George RE, Yu AL.

Clin Cancer Res. 2012 May 15;18(10):2740-53. doi: 10.1158/1078-0432.CCR-11-1939. Review.

13.

Immunodiagnosis and immunotherapy of childhood malignancies.

Bernstein I, Kersey J, Seeger R, Andrews R.

Pediatr Clin North Am. 1985 Jun;32(3):575-99. Review.

PMID:
3889799
14.

Contemporary therapeutic options for children with high risk neuroblastoma.

Sterba J.

Neoplasma. 2002;49(3):133-40. Review.

PMID:
12097996
15.

Antibody-based immunotherapy in high-risk neuroblastoma.

Johnson E, Dean SM, Sondel PM.

Expert Rev Mol Med. 2007 Dec 17;9(34):1-21. Review.

PMID:
18081947
16.

Recombinant antibodies in the immunotherapy of neuroblastoma: perspectives of new developments.

Bestagno M, Occhino M, Corrias MV, Burrone O, Pistoia V.

Cancer Lett. 2003 Jul 18;197(1-2):193-8. Review.

PMID:
12880981
17.
18.

[Gangliosides and cancer].

Dumontet C, Portoukalian J.

Bull Cancer. 1991;78(9):789-99. Review. French.

PMID:
1751830
19.

Monoclonal antibody-based therapy of neuroblastoma.

Cheung NK, Kushner BH, Kramer K.

Hematol Oncol Clin North Am. 2001 Oct;15(5):853-66. Review.

PMID:
11765377
20.

The role of gangliosides in fenretinide-induced apoptosis of neuroblastoma.

Lovat PE, Corazzari M, Di Sano F, Piacentini M, Redfern CP.

Cancer Lett. 2005 Oct 18;228(1-2):105-10. Review.

PMID:
15907365
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk